Celgene acquires Delinia
Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia's co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene - now that's awesome!
|
|
|
David Seftel featured in San Francisco Chronicle
One of the great aspects of our community, are the wonderful people we work with. Reading the front page of the Chronicle recently, we discovered that Dr. David Seftel is not only a co-founder of Enable Biosciences, but he also has a storied past of resisting Apartheid in South Africa and then becoming the much loved doctor to the jockeys at Golden Gate Fields. Come say hello to him at Enable's seminar on the on the 22nd (see below). Read more
|
|
|
Alpine Roads
Alpine Roads is creating a more humane and sustainable food system by removing animals from the process of making food. Alpine is developing alternative ways to produce animal protein by nutritionally enhancing plants.
|
|
|
Wild Type
Wild Type is working to introduce a viable alternative to today's food ecosystem by providing delicious and sustainable meat to the world using cellular agriculture technology.
|
|
|
Please join us as we toast the growth and success of Perlara and Mission Bio and wish them well as they move to South San Francisco. Celebrations will be on Friday, February 10, 2017 at 3:30 PM.
RSVP
|
|
|
Seminar: February 2, 2017, 2 PM - 3 PM
Best Practices for Cash Management in a rising rate environment and an overview of the venture debt markets, options, terms, and solutions to maximize your cash runway
Benjamin Campbell, CEO
Matthew Morell, Vice President
Capital Advisors Group
|
|
You finally got a big round, enough cash to see you through the next 18-24 months. What should you do with it? Leave it in your checking account earning no interest? Or do what FedEx's founder did - go to Vegas? There is a third way. This seminar will cover how best to meet your fiduciary responsibilities and effectively manage your cash. Ben and Matt will also review the venture debt market as well.
RSVP
|
|
|
Seminar: February 9, 2017, 2 PM - 3 PM
Making the Most of the Online Fundraising Platforms
Swati Chaturvedi, CEO
Propel(x)
Online angel investing holds the promise of being an exciting new avenue for funding life-science startups. It's also a complex arena with a number of competing platforms. Swati will provide a roadmap for using online investment platforms to complement other efforts, and will highlight successful case studies, including startups at QB3@953.
RSVP
|
|
|
Seminar: February 22, 2017, 12:30 PM - 1:30 PM
Amgen Innovator Series
Enable Awesome: Bootstrapping a Diagnostic from Idea to Industry
David Seftel, CSO
Peter Robinson, CEO
Enable Biosciences
|
|
Sponsored by
Enable Biosciences is a recent addition to the QB3@953 family - a spinout from the PhD work of a pair of Berkeley / Stanford grad students. Come hear the story of how two scientists with no business background teamed up with a sports medicine physician from South Africa to build the next generation of diabetes-screening technologies.
Peter Robinson, PhD, is the CSO of Enable Biosciences. After completing his graduate work in chemistry at UC Berkeley and Stanford in 2016, he joined Enable Biosciences full-time. With Enable Biosciences, he won several startup competitions, including the Harvard Business School New Ventures Competition, the Diabetes Innovation Challenge, and the Stanford Predictives and Diagnostics Accelerator prize.
RSVP
|
|
|
Office Hours: February 24, 2017, 1 PM - 3 PM
Making the Most of the Online Fundraising Platforms
Greg Naeve, Head, Strategic Research Partnerships, San Francisco at Pfizer
Come meet Pfizer's head of research partnerships in the Bay Area, Greg Naeve.
To apply for Office Hours, please contact Linda Eng by February 15, 2017.
|
|
|
|
|
